Alphamab Oncology (HKG:9966)

Revenue by Segment

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017
Pharmaceuticals	566.24M	640.08M	218.77M	166.85M	146.02M
Pharmaceuticals Growth	-11.54%	192.58%	31.12%	14.26%	-
Total	566.24M	640.08M	218.77M	166.85M	146.02M
Total Growth	-11.54%	192.58%	31.12%	14.26%	-

Revenue by Geography

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	FY 2019	FY 2018	FY 2017
Period Ending	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019	Dec 31, 2018	Dec 31, 2017
People's Republic of China ("PRC")	566.24M	640.08M	218.77M	166.85M	146.02M
People's Republic of China ("PRC") Growth	-11.54%	192.58%	31.12%	14.26%	-
Total	566.24M	640.08M	218.77M	166.85M	146.02M
Total Growth	-11.54%	192.58%	31.12%	14.26%	-

Data Source: S&P Global Market Intelligence Last updated: Dec 31, 2025

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every six months for this company.

Update frequency:

Semi-annually

Last checked:

Jun 15, 2026

Data Sources Report a data error